Contract drug research and manufacturing firm Syngene International Ltd has lowered its full-year revenue guidance from mid-single digit growth to negative 2-3%, as destocking of a single biologics ...
Syngene International adapts to industry challenges, focusing on balanced growth in R&D and manufacturing. Biologics are a key growth driver for Syngene, with expanded capabilities for discovery and ...
Syngene International Ltd. is the country's largest integrated CRAMS/CRDMO, offering services to various sectors including pharmaceuticals, biotechnology, and consumer goods. Syngene International ...
Syngene International Ltd, a wholly owned subsidiary of Biocon Ltd, and Baxter International, a global pharmaceutical company, have collaborated to establish the Baxter Global Research Center at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results